{"entity":{"id":"paper-glow-zolbetuximab-nat-med-2023","kind":"paper","name":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","aka":[],"tldr":"Adding the claudin 18.2 antibody zolbetuximab to CAPOX chemotherapy lengthened survival in claudin 18.2-positive advanced gastric cancer, confirming the SPOTLIGHT result with a different chemotherapy backbone.","summary":"Phase 3 placebo-controlled trial of 507 patients with untreated claudin 18.2-positive (75 percent or more of tumour cells), HER2-negative locally advanced or metastatic gastric or junctional adenocarcinoma randomised to zolbetuximab or placebo with capecitabine and oxaliplatin.\n\nMedian progression-free survival was 8.21 versus 6.80 months (hazard ratio 0.687) and median overall survival 14.39 versus 12.16 months (hazard ratio 0.771); nausea and vomiting were the characteristic added toxicities.","asOf":"2026-09-17","links":[{"label":"Nat Med 2023","url":"https://doi.org/10.1038/s41591-023-02465-7"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37524953/"}],"tags":[],"related":[],"cancers":["gastric-cldn18-2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["zolbetuximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine"],"dependsOn":[],"notes":[],"journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02465-7","pmid":"37524953","authors":"Shah MA, Shitara K, Ajani JA, et al.","paperType":"rct","findings":["Median overall survival 14.39 vs 12.16 months; hazard ratio 0.771.","Median progression-free survival 8.21 vs 6.80 months."],"whatItMeans":"Zolbetuximab with either FOLFOX or CAPOX is a first-line standard for claudin 18.2-positive, HER2-negative gastric cancer, making claudin 18.2 testing routine.","caveats":["About 38 percent of screened patients were claudin 18.2-positive.","Nausea and vomiting in the first cycles lead to some discontinuation."],"changedPractice":true,"participants":507},"route":"/key-papers/paper-glow-zolbetuximab-nat-med-2023/","neighbours":{"cancer":[{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/"}],"drug":[{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"journal":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/"}]}}